Baird Initiates Coverage On Edwards Lifesciences with Outperform Rating, Announces Price Target of $107
Portfolio Pulse from richadhand@benzinga.com
Baird analyst David Rescott has initiated coverage on Edwards Lifesciences (NYSE:EW) with an Outperform rating and a price target of $107.
July 19, 2023 | 8:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edwards Lifesciences has been given an Outperform rating by Baird with a price target of $107.
The Outperform rating from Baird indicates a positive outlook for Edwards Lifesciences. The price target of $107 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100